CytoMed Therapeutics (GDTC) Cost of Revenue (2022 - 2024)
CytoMed Therapeutics (GDTC) posted Cost of Revenue of $5535.0 for Q2 2023, up 19.03% sequentially from $4650.0 in Q2 2022, and up 19.03% YoY from $4650.0 in Q2 2022.
CytoMed Therapeutics (GDTC) Cost of Revenue (2022 - 2024) Analysis & Trends
CytoMed Therapeutics has reported Cost of Revenue for 2 years, with the latest figure at $5535.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CytoMed Therapeutics | 10.72 Mn | 9.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 6,419.00 |
| Jun 30, 2024 | 6,419.00 |
| Jun 30, 2023 | 5,535.00 |
| Jun 30, 2023 | 5,535.00 |
| Jun 30, 2022 | 4,650.00 |
| Jun 30, 2022 | 4,650.00 |